483 related articles for article (PubMed ID: 12526306)
41. Oral immunization of raccoons and skunks with a canine adenovirus recombinant rabies vaccine.
Henderson H; Jackson F; Bean K; Panasuk B; Niezgoda M; Slate D; Li J; Dietzschold B; Mattis J; Rupprecht CE
Vaccine; 2009 Nov; 27(51):7194-7. PubMed ID: 19925952
[TBL] [Abstract][Full Text] [Related]
42. [Development and preliminary assessment of a recombinant canarypox virus as an antirabic vaccine candidate].
Zanetti F; Rudak L; Micucci M; Grand DC; Luque A; Russo S; Taboga O; Pérez O; Calamante G
Rev Argent Microbiol; 2012; 44(2):75-84. PubMed ID: 22997764
[TBL] [Abstract][Full Text] [Related]
43. Engineering of a recombinant trivalent single-chain variable fragment antibody directed against rabies virus glycoprotein G with improved neutralizing potency.
Turki I; Hammami A; Kharmachi H; Mousli M
Mol Immunol; 2014 Feb; 57(2):66-73. PubMed ID: 24091293
[TBL] [Abstract][Full Text] [Related]
44. Rabies DNA vaccination by the intranasal route in dogs.
Tesoro Cruz E; Hernández González R; Alonso Morales R; Aguilar-Setién A
Dev Biol (Basel); 2006; 125():221-31. PubMed ID: 16878480
[TBL] [Abstract][Full Text] [Related]
45. Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene.
Cenna J; Tan GS; Papaneri AB; Dietzschold B; Schnell MJ; McGettigan JP
Vaccine; 2008 Nov; 26(50):6405-14. PubMed ID: 18804506
[TBL] [Abstract][Full Text] [Related]
46. Expression and solubilization of insect cell-based rabies virus glycoprotein and assessment of its immunogenicity and protective efficacy in mice.
Ramya R; Mohana Subramanian B; Sivakumar V; Senthilkumar RL; Sambasiva Rao KR; Srinivasan VA
Clin Vaccine Immunol; 2011 Oct; 18(10):1673-9. PubMed ID: 21813661
[TBL] [Abstract][Full Text] [Related]
47. Induction of a protective immune response to rabies virus in sheep after oral immunization with transgenic maize, expressing the rabies virus glycoprotein.
Loza-Rubio E; Rojas-Anaya E; López J; Olivera-Flores MT; Gómez-Lim M; Tapia-Pérez G
Vaccine; 2012 Aug; 30(37):5551-6. PubMed ID: 22749836
[TBL] [Abstract][Full Text] [Related]
48. A novel rapid fluorescent focus inhibition test for rabies virus using a recombinant rabies virus visualizing a green fluorescent protein.
Khawplod P; Inoue K; Shoji Y; Wilde H; Ubol S; Nishizono A; Kurane I; Morimoto K
J Virol Methods; 2005 Apr; 125(1):35-40. PubMed ID: 15737414
[TBL] [Abstract][Full Text] [Related]
49. Production of rabies neutralizing antibody in hen's eggs using a part of the G protein expressed in Escherichia coli.
Motoi Y; Sato K; Hatta H; Morimoto K; Inoue S; Yamada A
Vaccine; 2005 Apr; 23(23):3026-32. PubMed ID: 15811649
[TBL] [Abstract][Full Text] [Related]
50. A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein.
Amann R; Rohde J; Wulle U; Conlee D; Raue R; Martinon O; Rziha HJ
J Virol; 2013 Feb; 87(3):1618-30. PubMed ID: 23175365
[TBL] [Abstract][Full Text] [Related]
51. Rabies virus glycoprotein and immune response pattern using recombinant protein or recombinant RNA viral vectors.
Astray RM; Ventini DC; Boldorini VL; Silva FG; Rocca MP; Pereira CA
Vaccine; 2014 May; 32(24):2829-32. PubMed ID: 24598721
[TBL] [Abstract][Full Text] [Related]
52. The influence of homologous vs. heterologous challenge virus strains on the serological test results of rabies virus neutralizing assays.
Moore SM; Ricke TA; Davis RD; Briggs DJ
Biologicals; 2005 Dec; 33(4):269-76. PubMed ID: 16168666
[TBL] [Abstract][Full Text] [Related]
53. A comparative approach between heterologous prime-boost vaccination strategy and DNA vaccinations for rabies.
Borhani K; Ajorloo M; Bamdad T; Mozhgani SH; Ghaderi M; Gholami AR
Arch Iran Med; 2015 Apr; 18(4):223-7. PubMed ID: 25841942
[TBL] [Abstract][Full Text] [Related]
54. Genetically modified rabies virus ERA strain is safe and induces long-lasting protective immune response in dogs after oral vaccination.
Shuai L; Feng N; Wang X; Ge J; Wen Z; Chen W; Qin L; Xia X; Bu Z
Antiviral Res; 2015 Sep; 121():9-15. PubMed ID: 26093157
[TBL] [Abstract][Full Text] [Related]
55. Generation and characterization of P gene-deficient rabies virus.
Shoji Y; Inoue S; Nakamichi K; Kurane I; Sakai T; Morimoto K
Virology; 2004 Jan; 318(1):295-305. PubMed ID: 14972555
[TBL] [Abstract][Full Text] [Related]
56. Immunogenic and antigenic properties of recombinant soluble glycoprotein of rabies virus.
Gupta PK; Sharma S; Walunj SS; Chaturvedi VK; Raut AA; Patial S; Rai A; Pandey KD; Saini M
Vet Microbiol; 2005 Jul; 108(3-4):207-14. PubMed ID: 15916870
[TBL] [Abstract][Full Text] [Related]
57. DNA vaccine for rabies: relevance of the trans-membrane domain of the glycoprotein in generating an antibody response.
Rath A; Choudhury S; Batra D; Kapre SV; Rupprecht CE; Gupta SK
Virus Res; 2005 Nov; 113(2):143-52. PubMed ID: 15978691
[TBL] [Abstract][Full Text] [Related]
58. Rabies-virus-glycoprotein-pseudotyped recombinant baculovirus vaccine confers complete protection against lethal rabies virus challenge in a mouse model.
Wu Q; Yu F; Xu J; Li Y; Chen H; Xiao S; Fu ZF; Fang L
Vet Microbiol; 2014 Jun; 171(1-2):93-101. PubMed ID: 24793501
[TBL] [Abstract][Full Text] [Related]
59. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
[TBL] [Abstract][Full Text] [Related]
60. Peptide mimotopes of rabies virus glycoprotein with immunogenic activity.
Houimel M; Dellagi K
Vaccine; 2009 Jul; 27(34):4648-55. PubMed ID: 19520204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
